Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIRECTION: AbobotulinumtoxinA vs OnabotulinumtoxinA in Upper Limb Spasticity
NCT04936542Phase 4Completed
- Sponsor
- Ipsen
- Start
- Jun 2021
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 4, randomised, double-blind trial of abobotulinumtoxinA in Upper limb spasticity (2 arms), sponsored by Ipsen. Primary endpoint: Treatment-Emergent Adverse Events at 12 weeks. Started Jun 2021; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
Upper limb spasticity
Beyond the preview
Go deeper on NCT04936542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04936542.